Related Experiment Videos
Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology
Insights
The 2013 American guidelines for high cholesterol treatment shift to risk reduction, potentially increasing statin use in primary prevention. European guidelines are recommended for the Spanish population to avoid overtreatment and ensure adherence.
Area of Science:
- Cardiology
- Preventive Medicine
- Clinical Practice Guidelines
Background:
- The 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines introduced a paradigm shift.
- These guidelines moved from a low-density lipoprotein cholesterol (LDL-C) treat-to-target strategy to a risk reduction approach for statin therapy.
- This shift prompted a review and comparison with existing European guidelines by Spanish cardiovascular prevention experts.
Framework:
- The ACC/AHA guidelines eliminate the low-density lipoprotein cholesterol (LDL-C) treat-to-target strategy.
- A risk reduction strategy is adopted, identifying four major statin benefit groups.
Implementation:
- Both guidelines recommend high-dose statins for established cardiovascular disease.
- The ACC/AHA guidelines may significantly increase statin use in primary prevention, particularly among older adults.
- The elimination of the LDL-C treat-to-target strategy may cause confusion and reduce patient adherence.
Implications:
- European guidelines are recommended for the Spanish setting due to their appropriateness for the native population.
- European guidelines help avoid potential overtreatment with statins in primary prevention.
- Reaffirmation of European guidelines supports clarity and adherence in clinical practice.
Abstract:
The publication of the 2013 American College of Cardiology/American Heart Association guidelines on the treatment of high blood cholesterol has had a strong impact due to the paradigm shift in its recommendations. The Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology reviewed this guideline and compared it with current European guidelines on cardiovascular prevention and dyslipidemia management. The most striking aspect of the American guideline is the elimination of the low-density lipoprotein cholesterol treat-to-target strategy and the adoption of a risk reduction strategy in 4 major statin benefit groups. In patients with established cardiovascular disease, both guidelines recommend a similar therapeutic strategy (high-dose potent statins). However, in primary prevention, the application of the American guidelines would substantially increase the number of persons, particularly older people, receiving statin therapy. The elimination of the cholesterol treat-to-target strategy, so strongly rooted in the scientific community, could have a negative impact on clinical practice, create a certain amount of confusion and uncertainty among professionals, and decrease follow-up and patient adherence. Thus, this article reaffirms the recommendations of the European guidelines. Although both guidelines have positive aspects, doubt remains regarding the concerns outlined above. In addition to using risk charts based on the native population, the messages of the European guideline are more appropriate to the Spanish setting and avoid the possible risk of overtreatment with statins in primary prevention.